BRPI0407726A - compostos, processo de preparação de um composto, composição farmacêutica e utilização de um composto - Google Patents

compostos, processo de preparação de um composto, composição farmacêutica e utilização de um composto

Info

Publication number
BRPI0407726A
BRPI0407726A BRPI0407726-1A BRPI0407726A BRPI0407726A BR PI0407726 A BRPI0407726 A BR PI0407726A BR PI0407726 A BRPI0407726 A BR PI0407726A BR PI0407726 A BRPI0407726 A BR PI0407726A
Authority
BR
Brazil
Prior art keywords
alkyl
optionally substituted
halogen
alkoxy
nhc
Prior art date
Application number
BRPI0407726-1A
Other languages
English (en)
Inventor
Lydie Poitout
Valerie Brault
Carole Sackur
Pierre Roubert
Pascale Plas
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of BRPI0407726A publication Critical patent/BRPI0407726A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS, PROCESSO DE PREPARAçãO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA E UTILIZAçãO DE UM COMPOSTO". A invenção refere-se a derivados inéditos de benzimidazol e imidazopiridina que apresentam uma boa afinidade com determinados subtipos de receptores de melanocortina, particularmente receptores MC4. Referidos derivados são particularmente interessantes para o tratamento de estados e doenças patológicas envolvendo um ou vários receptores de melanocortina. A invenção refere-se também a composições farmacêuticas contendo referidos produtos.
BRPI0407726-1A 2003-02-26 2004-02-25 compostos, processo de preparação de um composto, composição farmacêutica e utilização de um composto BRPI0407726A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0302320A FR2851563B1 (fr) 2003-02-26 2003-02-26 Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
PCT/FR2004/000418 WO2004075823A2 (fr) 2003-02-26 2004-02-25 Derives de benzimidazole et d’imidazo-pyridine ayant une addinite pour les recepteurs des melanocortines et leur utilisation en tant que medicament

Publications (1)

Publication Number Publication Date
BRPI0407726A true BRPI0407726A (pt) 2006-02-14

Family

ID=32799584

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407726-1A BRPI0407726A (pt) 2003-02-26 2004-02-25 compostos, processo de preparação de um composto, composição farmacêutica e utilização de um composto

Country Status (19)

Country Link
US (4) US7355052B2 (pt)
EP (1) EP1599167B1 (pt)
JP (1) JP4714673B2 (pt)
KR (1) KR101074579B1 (pt)
CN (1) CN1753670A (pt)
AT (1) ATE374754T1 (pt)
AU (1) AU2004216427B2 (pt)
BR (1) BRPI0407726A (pt)
CA (1) CA2516660C (pt)
DE (1) DE602004009294T2 (pt)
DK (1) DK1599167T3 (pt)
ES (1) ES2295826T3 (pt)
FR (1) FR2851563B1 (pt)
MX (1) MXPA05009015A (pt)
NZ (1) NZ541632A (pt)
PL (1) PL214244B1 (pt)
PT (1) PT1599167E (pt)
RU (1) RU2330023C2 (pt)
WO (1) WO2004075823A2 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833948B1 (fr) * 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
DE10349587A1 (de) * 2003-10-24 2005-05-25 Merck Patent Gmbh Benzimidazolylderivate
US7714009B2 (en) 2003-10-31 2010-05-11 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
EP1802623A1 (en) * 2004-10-12 2007-07-04 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
US7429608B2 (en) 2005-01-20 2008-09-30 Amgen Inc. Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments
GB0526042D0 (en) * 2005-12-21 2006-02-01 Syngenta Participations Ag Chemical compounds
WO2007091950A1 (en) * 2006-02-07 2007-08-16 Astrazeneca Ab Benzimidazoles and imidazopyridines useful in the treatment of diseases or disorders associated with cannabinoid receptor 2 (cb2) such as pain
US20110071130A1 (en) * 2006-05-08 2011-03-24 Pharmacopeia, Inc. 2-aminobenzimidazoles for treating neurodegenerative diseases
EP2072050A1 (en) 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Compounds with anti-emetic effect
EP2072516A1 (en) * 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8470819B2 (en) * 2008-11-03 2013-06-25 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
MX2011008674A (es) * 2009-02-18 2011-11-04 Amgen Inc Compuestos de indol/bencimidazol como inhibidores de quinasa mtor.
UY32470A (es) * 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
JP5868851B2 (ja) * 2009-06-23 2016-02-24 ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート ベンズアミド誘導体
FR2955105B1 (fr) 2010-01-11 2012-04-20 Arkema France Procede de preparation d'aminoethyl imidazolidone ou de son thiocarbonyle
CA2789950C (en) 2010-02-18 2018-09-04 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
CA2803448A1 (en) * 2010-07-06 2012-01-12 Universite De Montreal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
SG10201505997TA (en) 2010-08-05 2015-09-29 Amgen Inc Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2013012848A1 (en) 2011-07-18 2013-01-24 Merck Patent Gmbh Benzamides
US20140315881A1 (en) * 2011-07-29 2014-10-23 Tempero Pharmaceuticals, Inc. Compounds and methods
KR102066297B1 (ko) 2011-10-14 2020-01-14 암비트 바이오사이언시즈 코포레이션 헤테로사이클릭 화합물 및 이의 유형 3 수용체 티로신 키나아제의 조절인자로서의 용도
SMT202100734T1 (it) 2011-12-29 2022-03-21 Rhythm Pharmaceuticals Inc Metodo di trattamento di disturbi associati al recettore di melanocortina 4 in portatori eterozigoti
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
RU2528110C1 (ru) * 2013-03-02 2014-09-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ увеличения скорости психомоторных реакций анксиолитиком афобазол
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP6538025B2 (ja) 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物
JP6622690B2 (ja) 2013-03-15 2019-12-18 リズム・ファーマシューティカルズ・インコーポレイテッド ペプチド組成物
CN104072395B (zh) * 2013-03-25 2016-08-24 黄蓬 一种异硫氰酸酯及其制备方法与抗癌应用
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN105017211A (zh) * 2014-04-30 2015-11-04 重庆华邦制药有限公司 一种2-苯基丙酸酯衍生物及其制备方法和用途
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
CN106397288B (zh) * 2015-07-31 2019-04-16 深圳超多维科技有限公司 联苯类液晶材料的制备方法
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN111471056B (zh) * 2019-01-23 2021-07-02 成都先导药物开发股份有限公司 一种大环类免疫调节剂
KR102266854B1 (ko) * 2019-11-06 2021-06-18 계명대학교 산학협력단 마약 중독 예방 또는 치료용 약학조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634066A1 (de) * 1986-10-07 1988-04-21 Boehringer Mannheim Gmbh Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel
RU2043344C1 (ru) * 1991-05-20 1995-09-10 Курский Государственный Медицинский Институт N-2-(1- r1-5-r2-6-r3- бензимидазолил)сукцинаминовые кислоты, проявляющие нейролептическую, антигипоксическую и антиаритмическую активность
NZ337749A (en) * 1997-05-01 2000-09-29 Nissan Chemical Ind Ltd Benzimidazole derivative and their use in allergy-related disease
EP1214330A1 (en) * 1999-09-21 2002-06-19 LION Bioscience AG Benzimidazole derivatives and combinatorial libraries thereof
EA200400595A1 (ru) * 2001-11-09 2004-10-28 Бёрингер Ингельхайм Фармасьютиклз, Инк. Бензимидазолы, применяемые в качестве ингибиторов протеинкиназы
FR2833948B1 (fr) * 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament

Also Published As

Publication number Publication date
CA2516660A1 (fr) 2004-09-10
DK1599167T3 (da) 2008-02-04
NZ541632A (en) 2008-09-26
US7501524B2 (en) 2009-03-10
US20050267147A1 (en) 2005-12-01
DE602004009294D1 (de) 2007-11-15
ES2295826T3 (es) 2008-04-16
US20050065179A1 (en) 2005-03-24
AU2004216427A1 (en) 2004-09-10
US20080139619A1 (en) 2008-06-12
EP1599167A2 (fr) 2005-11-30
CN1753670A (zh) 2006-03-29
CA2516660C (fr) 2013-12-03
RU2005129738A (ru) 2006-01-27
JP4714673B2 (ja) 2011-06-29
ATE374754T1 (de) 2007-10-15
PL214244B1 (pl) 2013-07-31
DE602004009294T2 (de) 2008-07-03
WO2004075823A2 (fr) 2004-09-10
US20090270372A1 (en) 2009-10-29
KR101074579B1 (ko) 2011-10-17
PL378288A1 (pl) 2006-03-20
US7816539B2 (en) 2010-10-19
JP2006519214A (ja) 2006-08-24
KR20050096192A (ko) 2005-10-05
FR2851563A1 (fr) 2004-08-27
EP1599167B1 (fr) 2007-10-03
WO2004075823A3 (fr) 2004-10-07
AU2004216427B2 (en) 2009-06-25
PT1599167E (pt) 2008-01-09
US7355052B2 (en) 2008-04-08
RU2330023C2 (ru) 2008-07-27
WO2004075823A8 (fr) 2004-10-28
FR2851563B1 (fr) 2005-04-22
US7501525B2 (en) 2009-03-10
MXPA05009015A (es) 2005-10-18

Similar Documents

Publication Publication Date Title
PL378288A1 (pl) Nowe pochodne benzoimidazolu oraz imidazo-pirydyny oraz ich zastosowanie jako leków
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
EA200400762A1 (ru) Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции
PH12012501351A1 (en) Synthesis of eporthilones, intermediates thereto, analogues and uses thereof
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
IL176247A0 (en) Cyclopropane compounds and pharmaceutical use thereof
PE20040644A1 (es) Nuevos derivados de quinuclidina-amina
EP3925614A3 (en) Melanocortin receptor ligands
ATE327229T1 (de) Verbindungen und deren verwendung als 5-ht inhibitore
UA85576C2 (ru) Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата
CA2495967A1 (fr) Nouveau procede de synthese et nouvelle forme cristalline de l'agomelatine ainsi que les compositions pharmaceutiques qui la contiennent
AU2003228770A8 (en) Substituted pyrazolopyrimidines
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
EP1666459A3 (en) Aminocyclohexyl ether compounds and uses thereof
DE50310161D1 (de) Kationisch substituierte diphenylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
TNSN04250A1 (en) Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof.
CY1112137T1 (el) Υποκατεστημενες σπειρο-ενωσεις και η χρηση αυτων για παραγωγη φαρμακευτικων μεσων εναντι πονου
BRPI0417157A (pt) composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
JO3360B1 (ar) الشكل البلوري الجديد 3 للأغوميلاتين وعملية تحضيره والمكونات الصيدلانية التي تحتويه
PT1583538E (pt) Utilização da 3-metoxi-pregnenolona para a preparação de um medicamento destinado a tratar as doenças neurodegenerativas
DE60215313D1 (de) Indolderivate und deren verwendung als gnrh antagonisten
MXPA04005313A (es) Derivados de aminotetralin como antagonistas del receptor muscarinico.
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
DE602004014727D1 (de) Aminoalkoholderivate, pharmazeutische zusammensetzungen, die diese enthalten, und verwendung davon
FR2862971B1 (fr) Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: IPSEN PHARMA S.A.S. (FR)

B25G Requested change of headquarter approved

Owner name: IPSEN PHARMA S.A.S. (FR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2364 DE 26-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.